Scarica l'app Stockscreener
0.9132
0.34%
-0.00315
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye - Streetwise Reports
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target - Investing.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye DiseaseSlideshow (NASDAQ:ALDX) 2026-09-30 - Seeking Alpha
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute ResolutionAldeyra Therapeutics (NASDAQ:AL - Benzinga
ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 - GuruFocus
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease - ophthalmologytimes.com
BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target - TradingView
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease - Yahoo Finance
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Aldeyra to appeal FDA rejection of dry eye drug reproxalap - Investing.com
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease - tradingview.com
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan
Aldeyra Therapeutics to Host Regulatory Update Webcast - FinancialContent
Aldeyra Therapeutics to Host Regulatory Update Webcast - Yahoo Finance
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast - TradingKey
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX: Aldeyra Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-09-06 | Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALDX | Press Release - stockhouse.com
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - vinanet.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
1.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):